EGFR and non-small cell lung carcinoma: Although the tumor microenvironment (TME) of EGFR-mutant NSCLC is immunosuppressive (28), EGFR-TKI may activate the TME by increasing dendritic cells and CD8+ cells, reducing Tregs, and inhibiting M2-like macrophages polarization at an early stage (35).